Formosa, DÁVI ink deal for clobetasol propionate ophthalmic suspension

Taiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with DÁVI Farmacêutica in Portugal for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05%. The drug is used to treat inflammation and pain following ocular surgery. 

Formosa noted that DÁVI is a trusted partner of Pharmathen Global Holding B.v., AZAD Pharma AG, NTC S.r.l. and Pfizer through marketing and promotion of Xalacom (Latanoprost + Timolol) and Xalatan (Latanoprost) for more than 12 years. DÁVI is one of the key players in the Portuguese market, with more than 100 years' history in the distribution and promotion of branded ophthalmology products, Formosa said. 

[Read more: Sun Pharma gets FDA green light for Xelpros]

Clobetasol propionate ophthalmic suspension (0.05%) was approved by the Food and Drug Administration in March, 2024, and was launched in the United States in September, 2024. The DÁVI licensing agreement includes upfront, commercialization milestones and sales milestones, with additional considerations throughout the term of the agreement.

"This partnership with DÁVI Farmacêutica, marks our first entry into a competitive EU market, opening the door for growth into other EU territories. DÁVI's experience and commitment to novel ophthalmic therapies is steadily apparent and Formosa Pharma appreciates their recognition of APP13007 as a worthy offering to patients recovering from ocular surgery," said Erick Co, president and CEO of Formosa Pharmaceuticals.

Rui Alves, business development manager of DÁVI Farmacêutica, said, "We are excited at DÁVI to be partnering with Formosa and have the opportunity to offer this cutting-edge drug and technology to our ophthalmologists and patients, reinforcing our strong position in the market and the commitment to enhance the well-being of our people."

[Read more: Alembic launches generic Temovate]